文献速递鼻科咽喉与嗓音

奥马珠单抗治疗NSAIDs加重呼吸道疾病患者的回顾性分析

Omalizumab in patients with NSAIDs-exacerbated respiratory disease.
PubMed 文献 · Rhinology · 2020-01-01

本研究回顾性分析奥马珠单抗治疗确诊NSAIDs加重呼吸道疾病(N-ERD)患者的临床疗效。16例患者接受奥马珠单抗治疗9个月,鼻部症状、鼻息肉评分、哮喘控制及肺功能均显著改善,荨麻疹症状3个月后消失;对照组鼻息肉评分无变化。结论认为奥马珠单抗是N-ERD的有效治疗选择。

要点

  • 奥马珠单抗治疗9个月显著改善N-ERD患者鼻部症状和鼻息肉评分。
  • 哮喘控制评分和FEV1显著提高,荨麻疹症状3个月后消失。
  • 对照組(阿司匹林脱敏)鼻息肉评分无变化,支持奥马珠单抗疗效。

核心结论

  • 奥马珠单抗在9个月研究期内是N-ERD患者的有效治疗选择。

研究设计与样本

  • 开放标签回顾性研究,纳入确诊N-ERD的CRSwNP患者,接受奥马珠单抗治疗16例(10女6男,平均年龄51岁),对照组为阿司匹林脱敏患者16例(8女8男,平均年龄45岁),随访9个月。

主要发现

  • 奥马珠单抗组CRS症状、RSOM-31评分和鼻息肉评分较基线显著下降。
  • ACT评分从平均16.5升至20.6,FEV1从平均80%升至89%,均显著改善。
  • 治疗3个月后无荨麻疹症状报告。
  • 1例需口服泼尼松治疗,另1例因鼻息肉进展需再次鼻窦手术。
  • 对照组鼻息肉评分无变化。

关键数值与推荐

  • 奥马珠单抗组鼻息肉评分显著下降,对照组无变化。
  • ACT评分平均从16.5改善至20.6,FEV1平均从80%改善至89%。

临床怎么用

  • 对于确诊N-ERD且反复鼻息肉、哮喘或荨麻疹的患者,可考虑奥马珠单抗治疗。
  • 治疗期间需监测鼻部症状、哮喘控制和肺功能,少数患者可能仍需手术或激素。

局限性

  • 回顾性开放标签研究,样本量较小(奥马珠单抗组16例,对照组16例),随访9个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association of acetylsalicylic acid (ASA) intolerance, chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, or chronic urticaria is known as NSAID-exacerbated respiratory disease (N-ERD). N-ERD patients often suffer from recurrent nasal polyps, severe asthma or also from urticaria. The aim of the present study was to retrospectively analyze the clinical efficacy of anti-IgE antibody treatment with omalizumab in patients with confirmed N-ERD. METHODS: In the open trial with patients receiving verum patients with CRSwNP, confirmed N-ERD by oral or nasal ASA challenges, asthma or chronic urticaria were included in the study. Rhinological and pulmonary parameters were evaluated before and after 3, 6 and 9 months of therapy by rhinological questionnaires (CRS VAS-scores and RSOM-31), nasal polyp (NP)-, ACT-scores and FEV1 values. Urticaria activity was monitored clinically. N-ERD patients with aspirin desensitization were included as control group (follow-up 9 months). RESULTS: In the omalizumab group 16 patients were included (10 female, 6 male, mean age 51 yrs). CRS symptoms, RSOM-31- and NP-score decreased significantly following omalizumab therapy compared to baseline. The ACT-score (MV 16.5 to 20.6) and FEV1values (MV 80 % to 89 %) improved significantly. No urticaria symptoms were reported after 3 months. Oral prednisolone therapy was required in one case and a repeated nasal sinus surgery in an additional case due to progression of NP. In the control group (8 female, 8 male, mean age 45 yrs) the NP-score was unchanged. CONCLUSIONS: Omalizumab is an effective therapy option in N-ERD patients in a 9 month study period.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Forster-Ruhrmann U, Stergioudi D, Pierchalla G, et al. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology. 2020. PMID: 32077449. doi:10.4193/Rhin19.318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。